Alicia Olivo compensation by year
NeoGenomics Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $512,672 | $522,500 |
| Bonus | $0 | $75,000 |
| Stock awards | $863,357 | $1,499,997 |
| Option awards | $415,255 | $749,848 |
| Non-equity incentive | $431,775 | $196,000 |
| Pension and deferred compensation | $0 | $0 |
| All other | $13,800 | $6,654 |
| Total | $2,236,859 | $3,049,999 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NeoGenomics Inc DEF 14A filed April 6, 2026, accession 0001077183-26-000014, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 63,238 | $743,679 | — |
| RSU | 59,382 | $698,332 | — |
| PSU | 19,508 | $229,414 | — |
| RSU | 16,886 | $198,579 | — |
| PSU | 12,665 | $148,940 | — |
| RSU | 12,665 | $148,940 | — |
| RSU | 8,977 | $105,569 | — |
| RSU | 6,841 | $80,450 | — |
| RSU | 6,503 | $76,475 | — |
| RSU | 2,646 | $31,117 | — |
| Option | 16,140 | — | $16.45 |
| Option | 13,833 | — | $10.05 |
Per the Outstanding Equity Awards at Fiscal Year-End table in NeoGenomics Inc's FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 15 award rows shown.
Insider transactions since the last proxy
5 Form 4 lines since the FY2025 proxy (filed April 6, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-01 | Tax withholding | — | 2,692 | $0.00 | 90,875 |
| 2026-05-11 | Exercise or conversion | — | 3,944 | $0.00 | 96,126 |
| 2026-05-11 | Tax withholding | — | 2,559 | $0.00 | 93,567 |
| 2026-05-11 | Exercise or conversion derivative | — | 3,944 | $0.00 | 2,559 |
| 2026-05-01 | Tax withholding | — | 1,042 | $0.00 | 92,182 |
The 5 most recent of 5 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments NeoGenomics discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Resignation for good reason, no change in control | $540,000 | $1,270,042 | $29,272 | $2,163,314 |
| Involuntary termination without cause | $540,000 | $1,270,042 | $29,272 | $2,163,314 |
| Change in control and resignation for good reason | $1,080,000 | $2,014,062 | $29,272 | $3,447,334 |
| Change in control and involuntary termination | $1,080,000 | $2,014,062 | $29,272 | $3,447,334 |
Per the Potential Payments Upon Termination or Change in Control table in NeoGenomics Inc's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
NeoGenomics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Tony Zook | Director and Chief Executive Officer | $9,127,092 |
| Warren Stone | President and Chief Operating Officer | $5,068,830 |
| Jeffrey Sherman | Chief Financial Officer | $4,681,428 |
| Christopher Smith | Former Director and Former Chief Executive Officer | $4,045,937 |
| Melody Harris | Former Chief Operations Officer and President, Oncology Data Solutions | $3,692,445 |
| Alicia Olivo · this page | Executive Vice President, General Counsel & Business Development | $3,049,999 |
| Gary Passman | Chief Culture Officer | $2,443,195 |
The full NeoGenomics compensation record
free company briefThis page is one person within NeoGenomics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order NeoGenomics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NeoGenomics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat